Clinical effect of radiofrequency ablation combined with transcatheter arterial chemoembolization for patients ;with hepatocellular carcinoma
10.3760/cma.j.issn.1008-6706.2015.21.005
- VernacularTitle:射频消融术联合肝动脉介入术治疗原发性肝癌的临床观察
- Author:
Yue LOU
- Publication Type:Journal Article
- Keywords:
Radiofrequency ablation;
TACE;
Hepatocellular neoplasm
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;(21):3214-3216
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the safety and feasibility of radiofrequency ablation (RFA)combined with transcatheter arterial chemoembolization(TACE)for patients with primary liver carcer(PLC).Methods 64 cases with PLC were selected and randomly divided into two groups,32 cases in each group.The observation group accepted TACE combined with RFA therapy,while the control group only received TACE treatment.Term efficacy (after 1 year)and 1,2,3 -year survival rate were compared in the two groups.The changes of liver function parameters including aspartate aminotransferase (AST),alanine aminotransferase (ALT) and γ-aminoacyl transferase (γ-GT)of the two groups were analyzed and compared.Results After 1 year of treatment,the remission rate was 71.9% (23 /32)in the observation group,which in the control group was 43.8% (14 /32),the difference was statis-tically significant (χ2 =5.189,P <0.05).The 1,2,3 -year cumulative survival rates were 65.6% (21 /32),65.6%(21 /32)and 62.5% (20 /32)in the observation group,which in the control group were 37.5% (12 /32),28.1%(9 /32)and 21.9% (7 /32),the differences were statistically significant (χ2 =5.067,9.035,10.83,all P <0.05). After 2 months of treatment,AST,ALT and γ-GT levels in the observation group were significantly higher than those in the control group(t =4.218,2.449,8.647,all P <0.05).Conclusion TACE combined with RFA therapy can significantly improve the clinical symptoms of patients with PLC,which can improve liver function in patients and help prolong the survival time.
